Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Feb;53(2):828-31.
doi: 10.1128/AAC.00927-08. Epub 2008 Dec 1.

Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects

Nguyen Trong Chinh  1 , Nguyen Ngoc Quang, Nguyen Xuan Thanh, Bui Dai, Jason P Geue, Russell S Addison, Thomas Travers, Michael D Edstein
Affiliations
Randomized Controlled Trial

Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects

Nguyen Trong Chinh et al. Antimicrob Agents Chemother. 2009 Feb.

Abstract

The two fixed-dose combinations of dihydroartemisinin and piperaquine (Artekin and Arterakine) were found to be bioinequivalent in healthy Vietnamese subjects. However, because the peak plasma concentrations and areas under the concentration-time curves of dihydroartemisinin and piperaquine were only marginally different between the two formulations, similar therapeutic efficacies are expected in the treatment of malaria infections.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Mean (standard error of the mean) plasma dihydroartemisinin concentration-time profiles following the administration of a single oral dose of three Arterakine (•) or Artekin (○) tablets to 24 healthy Vietnamese subjects.
FIG. 2.
FIG. 2.
Mean (standard error of the mean) plasma piperaquine concentration-time profiles following the administration of a single oral dose of three Arterakine (•) or Artekin (○) tablets to 24 healthy Vietnamese subjects.
See this image and copyright information in PMC

References

    1. Ahmed, T., P. Sharma, A. Gautam, B. Varshney, M. Kothari, S. Ganguly, J. J. Moehrle, J. Paliwal, N. Saha, and V. Batra. 2008. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J. Clin. Pharmacol. 48:166-175. - PubMed
    1. Ashley, E. A., R. McGready, R. Hutagalung, L. Phaiphun, T. Slight, S. Proux, K. L. Thwai, M. Barends, S. Looareesuwan, N. J. White, and F. Nosten. 2005. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin. Infect. Dis. 41:425-432. - PubMed
    1. Denis, M. B., T. M. Davis, S. Hewitt, S. Incardona, K. Nimol, T. Fandeur, Y. Poravuth, C. Lim, and D. Socheat. 2002. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin. Infect. Dis. 35:1469-1476. - PubMed
    1. Food and Drug Administration. 2003. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products—general considerations. Food and Drug Administration, Washington, DC.
    1. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics. Marcel Dekker Inc., New York, NY.

Publication types

LinkOut - more resources